This is a Justification and Approval (J&A) document related to a government procurement. The purpose is to extend the period of performance for the procurement of Inmazeb. No specific details on how to win or what is needed are provided in this summary.
Line Items
Item
Qty
Unit
Est. Unit Price
Est. Total
Category
Inmazeb (Atoltivimab, Maftivimab, Odesivimab) - Extended Period of Performance
1
lot
$1,500,000.00
$1,500,000.00
Medical
Estimated Bid Value
$1,500,000.00
Want the full details?
Sign up free to see the agency name and the original bid posting link. Pro adds the 1 document, contracting-officer contacts and AI response outlines.